瑞舒伐他汀在高龄老年高胆固醇血症患者的应用

Application of rosuvastatin in aged patients with hypercholesterolemia

目的：评价瑞舒伐他汀治疗老年人高胆固醇血症的疗效及安全性。方法：对62例老年高胆固醇血症患者使用瑞舒伐他汀治疗,比较治疗前后血脂、肝功、肌酸磷酸肌酶、肌酐等的变化。结果：老年高胆固醇血症患者使用瑞舒伐他汀治疗2周后,总胆固醇[TC（5.58±1.11）mmol/L：（6.39±1.10）mmol/L]、低密度脂蛋白胆固醇水平[LDL-C（3.12±0.87）mmol/L：（4.22±0.91）mmol/L]较治疗前明显下降（P均〈0.05）;12周后,TC[（4.59±0.99）mmol/L：（6.39±1.10）mmol/L]、甘油三酯[（1.76±0.70）mmol/L：（2.20±0.78）mmol/L]、LDL-C水平[（2.30±0.78）mmol/L：（4.22±0.91）mmol/L]较治疗前明显下降（P均〈0.05~〈0.01）,高密度脂蛋白胆固醇较治疗前明显升高[（1.28±0.25）mmol/L：（1.09±0.21）mmol/L,P〈0.01]。所有患者对瑞舒伐他汀有良好耐受及很好的服药依从性,未发现药物相关的严重不良反应。结论：瑞舒伐他汀能全面改善老年高胆固醇血症患者血脂水平,并有良好的安全性。

Objective：To evaluate the efficacy and safety of rosuvastatin in treatment of elderly patients with hypercholesterolemia.Methods：A total of 62 aged patients with hypercholesterolemia received the treatment with rosuvastatin.The changes in total cholesterol（TC）,triglyceride（TG）,low density lipoprotein-cholesterol（LDL-C）,high density lipoprotein-cholesterol（HDL-C）,glutamic-oxaloacetic transaminase（GOT）,glutamate-pyruvate transaminase（GPT）,creatine kinase（CK） and creatinine（Cr） were compared before and after treatment.Results：After 2-week treatment with rosuvastatin the levels of TC [（5.58±1.11） mmol/L vs.（6.39±1.10） mmol/L]、LDL-C [（3.12±0.87） mmol/L vs.（4.22±0.91） mmol/L] significantly decreased compared with before treatment（P〈0.05 all）;after 12-week treatment with rosuvastatin,the levels of TC [（4.59±0.99） mmol/L vs.（6.39±1.10） mmol/L],TG [（1.76±0.70） mmol/L vs.（2.20±0.78） mmol/L] and LDL-C [（2.30±0.78） mmol/L vs.（4.22±0.91） mmol/L] significantly decreased（P〈0.05〈0.01）.,the level of HDL-C significantly increased compared with before treatment [（1.28±0.25） mmol/L vs.（1.09±0.21） mmol/L,P0.01].All patients showed good compliance and tolerance with rosuvastatin.No adverse drug reaction was observed.Conclusion：Rosuvastatin may improve the overall lipid profile in aged patients with hypercholesterolemia and possess reliable safety.